MedKoo Cat#: 126693 | Name: PF-06649298
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-06649298 is a solute carrier 13 member 5 (SLC13A5) inhibitor for the treatment of hyperlipidemia.

Chemical Structure

PF-06649298
PF-06649298
CAS#1854061-16-7

Theoretical Analysis

MedKoo Cat#: 126693

Name: PF-06649298

CAS#: 1854061-16-7

Chemical Formula: C16H22O5

Exact Mass: 294.1467

Molecular Weight: 294.35

Elemental Analysis: C, 65.29; H, 7.53; O, 27.18

Price and Availability

Size Price Availability Quantity
5mg USD 700.00 2 Weeks
10mg USD 1,250.00 2 Weeks
25mg USD 2,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PF-06649298; PF 06649298; PF06649298
IUPAC/Chemical Name
(R)-2-(4-(tert-butyl)phenethyl)-2-hydroxysuccinic acid
InChi Key
QNFWRHKLBLSSPB-MRXNPFEDSA-N
InChi Code
InChI=1S/C16H22O5/c1-15(2,3)12-6-4-11(5-7-12)8-9-16(21,14(19)20)10-13(17)18/h4-7,21H,8-10H2,1-3H3,(H,17,18)(H,19,20)/t16-/m1/s1
SMILES Code
O=C(O)[C@@](O)(CCC1=CC=C(C(C)(C)C)C=C1)CC(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 294.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rives ML, Shaw M, Zhu B, Hinke SA, Wickenden AD. State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281. Mol Pharmacol. 2016 Dec;90(6):766-774. doi: 10.1124/mol.116.106575. Epub 2016 Oct 17. PMID: 27754898. 2: Pajor AM, de Oliveira CA, Song K, Huard K, Shanmugasundaram V, Erion DM. Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors. Mol Pharmacol. 2016 Dec;90(6):755-765. doi: 10.1124/mol.116.105049. Epub 2016 Sep 28. PMID: 27683012. 3: Riccardi K, Li Z, Brown JA, Gorgoglione MF, Niosi M, Gosset J, Huard K, Erion DM, Di L. Determination of Unbound Partition Coefficient and in Vitro-in Vivo Extrapolation for SLC13A Transporter-Mediated Uptake. Drug Metab Dispos. 2016 Oct;44(10):1633-42. doi: 10.1124/dmd.116.071837. Epub 2016 Jul 14. PMID: 27417179. 4: Huard K, Gosset JR, Montgomery JI, Gilbert A, Hayward MM, Magee TV, Cabral S, Uccello DP, Bahnck K, Brown J, Purkal J, Gorgoglione M, Lanba A, Futatsugi K, Herr M, Genung NE, Aspnes G, Polivkova J, Garcia-Irizarry CN, Li Q, Canterbury D, Niosi M, Vera NB, Li Z, Khunte B, Siderewicz J, Rolph T, Erion DM. Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family. J Med Chem. 2016 Feb 11;59(3):1165-75. doi: 10.1021/acs.jmedchem.5b01752. Epub 2016 Jan 27. PMID: 26734723.